期刊
SURVEY OF OPHTHALMOLOGY
卷 63, 期 5, 页码 638-645出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.survophthal.2018.02.004
关键词
age-related macular degeneration; vascular endothelial growth factor; ranibizumab; lucentis; aflibercept; eylea; switch; refractory
资金
- Novartis
The introduction of antivascular endothelial growth factor agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age -related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date show that efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. Based on the published literature to date, we propose arguments for and against switching antivascular endothelial growth factor agents, provide our own perspective on this topic, and suggest a focus for future research. (C) 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据